Additionally, the two recognized medicines for IPF, namely pirfenidone and nintedanib, which are potent inhibitors of TGF-β and tyrosine-kinase respectively, inhibit collagen production (Yoon et al., 2018[64]). This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.